NEW YORK (GenomeWeb News) – Genetic Technologies today said that it has reached a settlement with Roche 454 Life Sciences over alleged infringement of Genetic Technologies' primary non-coding DNA patent.

The Australian firm said that it has reached a settlement, covenant, and license agreement with 454, which also covers its affiliates within Roche. The terms of the agreement are confidential.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.